• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

    4/29/25 11:10:00 AM ET
    $ICAD
    $PHG
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Health Care
    Get the next $ICAD alert in real time by email

    Equity Insider News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies, Inc. (OTCQB:AVAI), Koninklijke Philips N.V. (NYSE:PHG), HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), RadNet, Inc. (NASDAQ:RDNT), and iCad, Inc. (NASDAQ:ICAD).

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    The article continued: Barclays analysts forecast that the AI healthcare market will expand at a robust 30% CAGR through 2030, as investment from hospitals, insurers, and pharmaceutical giants continues to climb. A recent Deloitte study further notes that 71% of healthcare executives expect profitability to rise this year, in large part due to the growing integration of AI technologies into clinical operations.

    Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology

    Avant Technologies, Inc. (OTCQB:AVAI), an emerging leader in AI-driven healthcare innovation, and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) has received the company's submission package requesting a pre-submission meeting with the FDA for its VisionAI platform technology and is now under review.

    Ainnova is requesting a pre-submission meeting with the FDA's review team to discuss any questions and/or concerns about its proposed formal submission, including seeking advice to finalize the protocol and obtain agency guidance for a clinical trial of its VisionAI platform in the early detection of diabetic retinopathy. A pre-submission meeting allows companies to clarify regulatory requirements, get feedback on their plans, and potentially avoid delays or issues during the formal review process.

    The clinical studies will aim to support an FDA 510(k) submission to obtain clearance from the regulatory agency to market its technology in the U.S.

    Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, including its VisionAI platform and its versatile retinal cameras, has worldwide licensing rights for this portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States.

    "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."

    For medical device applicants like Ainnova, the FDA's pre-submission program is useful to determine a clear regulatory pathway for the successful launch of the device, including the number of patients and the number of clinics that will be needed to generate the necessary clinical data for the FDA to make an informed decision on Ainnova's VisionAI platform.

    For Avant, the pre-submission meeting will help define a precise budget for the strategic partnership's entire FDA process.

    This follows Ainnova's recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas. Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

    Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.

    Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.

    CONTINUED... Read this and more news for Avant Technologies at:

    https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

    Philips N.V. (NYSE:PHG) recently announced an expanded partnership with Ibex Medical Analytics to enhance its AI-enabled digital pathology workflows. Their integrated solution helps pathology labs detect cancers more quickly and accurately while boosting productivity by up to 37%.

    "Pathology provides key information for a precise diagnosis," said Sam Terese, President & CEO of Alverno Laboratories. "The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis. These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases."

    The new PIPS 6.0 system includes cloud archiving, better AI integration, and optimized case management tools. These improvements are designed to ease the growing workload on pathologists and improve patient outcomes worldwide.

    HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF) recently completed its acquisition of Orion Health, significantly expanding its global footprint in healthcare data interoperability and AI-driven solutions. The deal brought access to a large base of public sector clients and 150 million patient records worldwide, strengthening HEALWELL's platform for actionable healthcare insights.

    "The acquisition of Orion Health represents a transformative milestone for the Company, bringing large enterprise customers, recurring revenues, strong operating margins and free cashflow conversion to HEALWELL while providing a significant new channel for the distribution of our best-in-class AI products," said Dr. Alexander Dobranowski, CEO of HEALWELL. "In addition, the acquisition strengthens our position in the public sector, enabling us to deepen our reach with government partners, thanks to Orion Health's strong, long-standing relationships. With the added synergies from WELL Health, we are poised to transform healthcare through AI and data-driven innovation."

    RadNet, Inc. (NASDAQ:RDNT) recently announced plans to acquire iCad, Inc. (NASDAQ:ICAD), aiming to strengthen its leadership in AI-powered breast cancer detection and diagnosis.

    "With over 1,500 healthcare provider locations, facilitating over 8 million annual mammograms in 50 countries, iCAD's installed base and strong sales, engineering and marketing capabilities will provide us with immediate broad and valuable customer relationships and commercialization capabilities that can accelerate our existing DeepHealth objectives," said Dr. Howard Berger, President and CEO of RadNet. "This business combination is expected to accelerate our global leadership and commitment to AI-powered breast cancer screening, and positions us to further advance population health."

    The deal will add iCAD's global network of over 1,500 healthcare locations to RadNet's DeepHealth platform, expanding access to advanced screening technologies. The companies believe the combination will speed up innovation, improve early cancer detection, and enhance patient outcomes worldwide.

    Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo: https://mma.prnewswire.com/media/2644233/5292806/Equity_Insider_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-ai-platforms-expand-globally-amid-regulatory-and-market-tailwinds-302441473.html

    SOURCE Equity Insider

    Get the next $ICAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICAD
    $PHG
    $RDNT

    CompanyDatePrice TargetRatingAnalyst
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Neutral
    BTIG Research
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Hold
    Laidlaw
    RadNet Inc.
    $RDNT
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/25/2025Neutral → Outperform
    Exane BNP Paribas
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/20/2025Neutral → Buy
    UBS
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    10/29/2024Underperform → Hold
    Jefferies
    RadNet Inc.
    $RDNT
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    5/13/2024Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $ICAD
    $PHG
    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures

      May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. T

      5/20/25 8:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

      May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real timeCatheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United State

      5/19/25 4:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects

      May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the "Notes") under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in Philips' Sustainable Finance Framework. The issue price for the Notes due 2030 is 99.859% with a Coupon of 3.250%, resulting in a yield of 3.281% and the issue price for the Notes due 2035 is 99.595% wi

      5/15/25 3:00:00 PM ET
      $PHG
      Medical Electronics
      Health Care

    $ICAD
    $PHG
    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iCAD downgraded by BTIG Research

      BTIG Research downgraded iCAD from Buy to Neutral

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD downgraded by Laidlaw

      Laidlaw downgraded iCAD from Buy to Hold

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • RadNet upgraded by Raymond James with a new price target

      Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

      3/5/25 7:50:00 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $ICAD
    $PHG
    $RDNT
    SEC Filings

    See more
    • Amendment: SEC Form S-4/A filed by RadNet Inc.

      S-4/A - RadNet, Inc. (0000790526) (Filer)

      5/19/25 5:23:08 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

      6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

      5/16/25 7:45:44 AM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form 425 filed by RadNet Inc.

      425 - RadNet, Inc. (0000790526) (Filed by)

      5/13/25 5:15:01 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $ICAD
    $PHG
    $RDNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care
    • iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

      NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

      4/8/25 10:19:01 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Philips proposes new Supervisory Board appointments and reappointments, and Board of Management reappointment

      Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips' Supervisory Board at the end of the Annu

      2/19/25 1:05:00 AM ET
      $PHG
      Medical Electronics
      Health Care

    $ICAD
    $PHG
    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres & COO-Eastern Operations Forthuber Stephen M converted options into 2,760 shares and sold $1,135,599 worth of shares (18,820 units at $60.34), decreasing direct ownership by 3% to 535,182 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/20/25 4:15:10 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Levitt Lawrence L sold $305,450 worth of shares (5,000 units at $61.09), decreasing direct ownership by 3% to 164,957 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/20/25 4:15:08 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Pres and COO-West Operations Hames Norman R converted options into 2,760 shares and sold $506,820 worth of shares (8,447 units at $60.00), decreasing direct ownership by 1% to 249,183 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/15/25 8:43:59 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $ICAD
    $PHG
    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/12/24 4:51:53 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/4/24 1:22:38 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      10/24/24 6:36:21 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $ICAD
    $PHG
    $RDNT
    Financials

    Live finance-specific insights

    See more
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹

      First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditionsTotal Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024Revenue from the Digital Health reportable segment increased 31.1% to $19.2 million in the first quarter of 2025 from $14.7 million in the first quarter of 2024Aggregate procedural volumes increased 3.6% and same-center procedural volumes decreased 0.3% compared with the first quarter of 2024Total Company Adjusted EBITDA(1) was $4

      5/11/25 4:00:00 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Philips delivers on Q1 results, with ongoing order intake growth

      May 6, 2025Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasingComparable order intake increased 2% despite China declineIncome from operations increased to EUR 154 millionAdjusted EBITA margin declined 80 bps to 8.6% of sales, driven by sales phasingFree cash outflow of EUR 1,091 million included EUR 1,025 million payment for Philips Respironics recall-related medical monitoring and personal injury settlements in USUpdated full year 2025 outlook for Adjusted EBITA margin and free cash flow; sales outlook remains unchanged Roy Jakobs,

      5/6/25 1:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care